/ /

CLINICAL

The dangers of starting and stopping glaucoma treatmentThe notion of patients not coming in as advised for eye examinations can be troubling. For example, when a patient has an eye disease as potentially significant as glaucoma and chooses to ignore its presence, there is cause for concern on the part of the doctor.
Testing at point of care for improved patient satisfaction, re-treatment ratesAfter spending a few months testing for dry eye and treating the tear film before doing preoperative measurements, the re-treatment rate dropped from 11% to 3%.
Applying micropulse transscleral cyclophotocoagulation for early-stage glaucoma Micropulse transscleral cyclophotocoagulation utilises a different delivery modality than its predecessor, continuous-wave laser cycloablation, to produce a biological reaction without the lethal effects caused by thermal buildup.
Hypersonic vitrector holds potential for multiple benefitsBausch + Lomb has introduced an ultrasonic-powered hypersonic vitrectomy system that is driven exclusively by the company’s Stellaris Elite Vision Enhancement System. It has a novel mechanism of action and is expected to offer advantages compared with guillotine vitrectors, according to the company.
Yet another new revolution in ocular surface imagingDuring the past two decades, an incredible number of imaging technologies have been developed for eye diseases, both for diagnosis and follow-up.
Novel DME treatment derives from multimodal activityALG-1001 is an integrin receptor inhibitor that acts to stabilize the retina’s response to diabetes-related hypoxic and oxidative stress, mitigating production of a host of molecules involved in the development of diabetic macular edema.
Investigational trials target VEGF/angiopoietin2 inhibition
Don’t let bad beauty habits suck the fun out of Halloween
Don’t let bad beauty habits suck the fun out of HalloweenWhether your Halloween makeup plans are glamorous or ghoulish, incorrect makeup practices are frightful for eye health.
Intravitreal brimonidine holds promise for slowing GA growthBrimonidine Drug Delivery System (Brimo DDS) in an intravitreally administered, sustained-release implant (Allergan) shows promise as a treatment for geographic atrophy (GA), secondary to age-related macular degeneration in a phase IIa clinical trial.
Novel brolucizumab fosters as real-world alternative for nAMDTopline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.